Stock Research: Ipsen

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Ipsen

ENXTPA:IPN FR0010259150
92
  • Value
    90
  • Growth
    39
  • Safety
    Safety
    81
  • Combined
    96
  • Sentiment
    73
  • 360° View
    360° View
    92
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Ipsen SA is a biopharmaceutical group specializing in specialty care. The company operates in the specialty care and consumer healthcare industries, with a focus on oncology, neurosciences, and rare diseases. It operates globally, with research and development centers in France, the United Kingdom, and the United States. In the last fiscal year, the company had a market cap of $10,169 million, profits of $3,060 million, and revenue of $3,701 million, with 5358 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 92 (better than 92% compared with alternatives) for 2025, overall professional sentiment and financial characteristics for the stock Ipsen are very positive. The 360° View is based on consolidating four consolidated indicators, with half of the indicators below and half above average for Ipsen. The consolidated Value Rank has an attractive rank of 81, which means that the share price of Ipsen is on the lower side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 81% of alternative stocks in the same industry. The company is also safely financed with a Safety rank of 90. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 73. But the consolidated Growth Rank has a low rank of 39, which means that the company is below average in terms of growth and momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. 61 of its competitors have better growth. ...read more

more
Index
CAC All
SBF 120
Employee Focus EU
Moonshot Tech
Renewables Users
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
81 86 67 82
Growth
39 47 21 75
Safety
Safety
90 69 54 62
Sentiment
73 27 48 80
360° View
360° View
92 74 45 98
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
23 11 24 19
Opinions Change
90 18 43 92
Pro Holdings
n/a 69 61 82
Market Pulse
79 49 71 41
Sentiment
73 27 48 80
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
81 86 67 82
Growth
39 47 21 75
Safety Safety
90 69 54 62
Combined
96 81 38 94
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
92 89 81 92
Price vs. Earnings (P/E)
52 53 52 79
Price vs. Book (P/B)
63 67 57 69
Dividend Yield
49 52 49 53
Value
81 86 67 82
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
22 47 46 20
Profit Growth
51 23 25 63
Capital Growth
54 80 7 88
Stock Returns
53 55 62 70
Growth
39 47 21 75
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
84 78 68 41
Refinancing
61 25 15 48
Liquidity
81 76 75 65
Safety Safety
90 69 54 62

Similar Stocks

Discover high‑ranked alternatives to Ipsen and broaden your portfolio horizons.

Rubis

ENXTPA:RUI
Country: France
Industry: Gas Utilities
Size: Medium
Full Stock Analysis

Synergie

ENXTPA:SDG
Country: France
Industry: HR- & Employment Services
Size: Medium
Full Stock Analysis

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.

BUSE:RICHTER
Country: Hungary
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Perrigo

NYSE:PRGO
Country: Ireland
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.